Adverse events after infusion of UCB-derived Treg by immunosuppression regimen
| . | Cyclosporine A + mycophenolate mofetil . | Sirolimus + mycophenolate mofetil . |
|---|---|---|
| Number of patients | 17 | 6 |
| Number of infusions, fresh/cryopreserved | 17/8 | 6/6 |
| Infusional toxicity, fresh/cryopreserved | ||
| Grade 1 | 6/3 | 1/1 |
| Grade 2 | 2/0 | 1/1 |
| Grade 3 | 1/2 | 0/0 |
| Grade 4 and 5 | 0/0 | 0/0 |
| Relapse | 7 | 1 |
| Opportunistic infection by day +100 | 8 | 1 |
| . | Cyclosporine A + mycophenolate mofetil . | Sirolimus + mycophenolate mofetil . |
|---|---|---|
| Number of patients | 17 | 6 |
| Number of infusions, fresh/cryopreserved | 17/8 | 6/6 |
| Infusional toxicity, fresh/cryopreserved | ||
| Grade 1 | 6/3 | 1/1 |
| Grade 2 | 2/0 | 1/1 |
| Grade 3 | 1/2 | 0/0 |
| Grade 4 and 5 | 0/0 | 0/0 |
| Relapse | 7 | 1 |
| Opportunistic infection by day +100 | 8 | 1 |
Treg indicates regulatory T cell; UCB, umbilical cord blood.